Policosanol
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound Class | A mixture of long-chain aliphatic primary alcohols — not a single molecule; no single CAS applies |
| Principal Component | Octacosanol (C28); with triacontanol (C30), hexacosanol (C26), and others |
| Sources | Sugar cane wax (Cuban material); also rice bran, wheat germ, beeswax |
| Typical Standardisation | Total policosanol by GC, with the aliphatic alcohol profile specified |
| Primary Applications | Historically marketed for cholesterol reduction — a claim that has failed independent replication |
| Proposed Mechanism | Postulated HMG-CoA reductase downregulation; never definitively established |
| Claim Strength (Overview) | Null for cholesterol lowering in independent trials, including trials using authentic Cuban material |
| Buy from Herbuno | Policosanol Extract Powder → |
Name origin: Policosanol simply means "many alcohols" — it is a mixture of long-chain aliphatic primary alcohols, dominated by octacosanol (28 carbons), with triacontanol, hexacosanol and others alongside. It is not a molecule and never was, and the composition of the mixture varies substantially with source material, which turns out to matter for the story this page has to tell. Traditional use: None. Policosanol is not a traditional remedy but a 20th-century commercial extract, developed and patented in Cuba from sugar cane wax and marketed from 1991 onward as a lipid-lowering agent. Research trajectory: This is one of the most instructive case studies in supplement science, and this page exists largely to tell it straight. Roughly eighty double-blind studies, enrolling thousands of patients, reported that policosanol lowered LDL cholesterol comparably to statins — a spectacular result for a natural product at 5–40 mg/day. Virtually all of these were conducted by a single research group in Cuba, using Cuban sugar cane policosanol, with the commercial patent-holder’s involvement. When independent investigators attempted replication from 2006 onward, the effect vanished. Commercial context: Herbuno lists policosanol because buyers ask for it. This page will not pretend the evidence supports the claim on which it is sold, and formulators should read it before positioning a product.
Evidence for Policosanol Applications
The independent replication attempts must be reported first, because they are the decisive evidence. A randomized, double-blind, placebo-controlled trial in ambulatory community-dwelling adults with mild hypercholesterolemia (n=40) assigned oral policosanol at 20 mg or placebo once daily for eight weeks and found no significant differences in the change in LDL cholesterol between groups, and no significant changes in total cholesterol, HDL cholesterol, triacylglycerol, C-reactive protein, or NMR-determined lipoprotein profiles; the authors concluded plainly that policosanol does not alter the serum lipid profile in adults with mild hypercholesterolemia (Dulin 2006 Am J Clin Nutr). Claim strength: Null.
The obvious defence — that non-Cuban policosanol is a different material — was tested and failed. Investigators obtained authentic Cuban sugar cane policosanol and gave 10 mg/day (a typical dose) or placebo, incorporated in margarine, to twenty-one hypercholesterolemic volunteers under supervision for 28 days in a randomized double-blind crossover design; body weights did not vary, and no significant difference was observed between treatment and control in plasma total, LDL-, or HDL-cholesterol or triacylglycerol. The authors concluded that the results show no beneficial effects of Cuban sugar cane policosanols and question the clinical usefulness of policosanol mixtures as cholesterol-lowering nutraceutical agents (Kassis 2006 Am J Clin Nutr). The "unique Cuban preparation" argument is therefore closed. Claim strength: Null.
The failure is not confined to two trials. Negative results have accumulated from the Netherlands (wheat germ policosanol), Germany (Cuban material tested across 10–80 mg — an eightfold dose range, still nothing), Canada, Australia, and South Africa, across sugar cane-, sunflower seed-, rice- and wheat germ-derived material, in animals and humans. When a compound fails across four source materials, an eightfold dose range, and multiple independent research groups on three continents, the honest conclusion is not "more research is needed" but "the original finding did not replicate." Claim strength: Null.
What makes this case so instructive is the shape of the evidence rather than any single result. Around eighty positive trials from one group with a commercial interest, versus a consistent null from every independent group that has looked. This is precisely the pattern that evidence-based medicine exists to detect, and it is a pattern formulators should learn to recognise: volume of positive studies is not the same as independent replication. Reviews now state that policosanol is not recommended as monotherapy for hypercholesterolemia. Claim strength: Null.
Is there anything left? Two threads deserve honest mention without being oversold. Policosanol has documented antiplatelet activity, reported as mediated via thromboxane A₂ — this is a real pharmacological effect, though it is a safety consideration as much as a benefit. And octacosanol specifically has a small, old, and unconvincing literature in exercise performance. Neither of these supports the claim on which policosanol is actually sold, and a formulator who moves the marketing to antiplatelet activity has moved into territory requiring far more caution, not less. Claim strength: Emerging (antiplatelet, mechanistic).
Dosage & Formulator Specification
Herbuno carries Policosanol Extract Powder. We are listing this ingredient with an explicit statement that its principal marketed claim — cholesterol reduction — has failed independent replication, including in trials using authentic Cuban sugar cane material. Buyers positioning a product on lipid-lowering grounds should read this page in full and should understand that the claim is not supportable on current evidence.
Dosing guidance cannot honestly be given for an indication the compound does not treat. The Cuban literature used 5–40 mg/day and reported dose-dependent LDL reduction across that range; the German independent trial tested 10–80 mg — double the top of that range — and found no significant change in cholesterol at any dose. There is therefore no dose at which the cholesterol claim becomes valid, and increasing the serving size is not a route to efficacy. Formulators should not present any policosanol serving as clinically validated for lipid management.
Analytical verification should specify total policosanol by gas chromatography with the full aliphatic alcohol profile — octacosanol, triacontanol, hexacosanol, dotriacontanol and others quantified individually — since the mixture composition varies materially with source (sugar cane, rice bran, wheat germ, beeswax) and a total figure conceals it. Source material must be documented. Given that the compound’s efficacy claim is unsupported regardless of composition, this specification discipline serves identity and consistency rather than potency.
Policosanol has been consistently well tolerated across the trial literature, including the negative trials, with no significant adverse events noted at 20 mg/day over eight weeks and at doses to 80 mg elsewhere. The one caution worth stating is the antiplatelet activity documented via thromboxane A₂ inhibition: this creates plausible additive bleeding risk alongside anticoagulant and antiplatelet medication, and warrants caution before surgery. That an ingredient is safe is not an argument for selling it on a claim that does not hold, and Herbuno’s position is that buyers deserve to know the evidence position before they build a product on it.
Frequently Asked Questions — Policosanol
Does policosanol lower cholesterol?
On independent evidence, no. Around eighty positive trials came from a single Cuban research group with a commercial interest. Every independent replication attempt — including one using authentic Cuban sugar cane material at a typical 10 mg dose, and a German trial testing 10 to 80 mg — found no significant effect on LDL, total cholesterol, HDL, or triglycerides.
Is the "authentic Cuban preparation" argument valid?
It was tested and it failed. Investigators specifically obtained authentic Cuban sugar cane policosanol and ran a randomized double-blind crossover trial. No significant difference in any lipid measure. The authors concluded the results question the clinical usefulness of policosanol as a cholesterol-lowering nutraceutical. That defence is closed.
Would a higher dose work?
No. The Cuban literature claimed dose-dependent effects across 5-40 mg/day. A German independent trial tested Cuban material from 10 to 80 mg — double the top of that range — and found no significant change in cholesterol at any dose. There is no dose at which the claim becomes valid.
Why does Herbuno list an ingredient it says does not work?
Because buyers ask for it, and because the honest thing is to supply it with the evidence stated plainly rather than to sell it on a claim that has failed replication. The pattern here — many positive studies from one commercially interested group, consistent nulls from everyone else — is one formulators should learn to recognise.
Related compounds: Phytosterols, Beta-Sitosterol, Coenzyme Q10, Oleuropein
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery